1. Home
  2. PIK3CA-Related Overgrowth Spectrum

PIK3CA-Related Overgrowth Spectrum
Symptoms, Doctors, Treatments, Advances & More

Find a DoctorCondition OverviewLatest AdvancesClinical TrialsTreatments

PIK3CA-Related Overgrowth Spectrum Overview

  • Top Doctors
  • Latest Advances
  • Clinical Trials
Save information for later
Sign Up

Learn About PIK3CA-Related Overgrowth Spectrum

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top PIK3CA-Related Overgrowth Spectrum Local Doctors?
Eric P. Winer
Elite in PIK3CA-Related Overgrowth Spectrum
Dr. Eric P. Winer
Oncology | Hematology Oncology
Elite in PIK3CA-Related Overgrowth Spectrum
Dr. Eric P. Winer
Oncology | Hematology Oncology

Yale University

35 Park St, 
New Haven, CT 
203-785-4191
Languages Spoken:
English
See accepted insurances

Eric Winer is an Oncologist and a Hematologist Oncology provider practicing medicine in New Haven, Connecticut. Dr. Winer is rated as an Elite provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, and Breast Cancer in Men.

Sara M. Tolaney
Elite in PIK3CA-Related Overgrowth Spectrum
Dr. Sara M. Tolaney
Oncology
Elite in PIK3CA-Related Overgrowth Spectrum
Dr. Sara M. Tolaney
Oncology

Dana-Farber Cancer Institute, Breast Oncology Program

450 Brookline Avenue, Susan F. Smith Center For Women's Cancers, 
Boston, MA 
617-632-2335
Languages Spoken:
English
See accepted insurances

Dr. Tolaney is Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School.  She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer.  She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy.She is a member of the National Cancer Institute Breast Cancer Steering Committee and is Vice Chair for Late-Stage Development in Breast Cancer in the Alliance for Clinical Trials in Oncology. Her research has been funded by the Breast Cancer Research Foundation and Susan G. Komen. She currently chairs multiple phase 3 trials in breast cancer and serves on several steering committees for practice-changing trials.  Her work has been published in journals such as the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, and others. She received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital. Dr. Tolaney is rated as an Elite provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. She is also highly rated in 16 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, and Triple-Negative Breast Cancer. Dr. Tolaney is board certified in Medical Oncology.

 
 
 
 
Learn about our expert tiers
Learn More
Sibylle F. Loibl
Elite in PIK3CA-Related Overgrowth Spectrum
Sibylle F. Loibl
Elite in PIK3CA-Related Overgrowth Spectrum
Sibylle F. Loibl
Martin Behaim Str 12, 
Neu Isenburg, HE, DE 

Sibylle Loibl practices practicing medicine in Neu Isenburg, Germany. Ms. Loibl is rated as an Elite expert by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. She is also highly rated in 17 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Triple-Negative Breast Cancer, Breast Cancer in Men, and Mastectomy.

View All Doctors
What are the Latest Advances for PIK3CA-Related Overgrowth Spectrum?
Multimodal artificial intelligence predicts PIK3CA mutation in breast cancer from digital pathology and clinical data: a multicenter study.
Multimodal artificial intelligence predicts PIK3CA mutation in breast cancer from digital pathology and clinical data: a multicenter study.
Journal: Cancer biology & medicine
Published: April 13, 2026
Integrative multi-omic analysis identified ERBB2 mutations and senescence-driven immune suppression as dual therapeutic targets in LAR triple-negative breast cancer.
Integrative multi-omic analysis identified ERBB2 mutations and senescence-driven immune suppression as dual therapeutic targets in LAR triple-negative breast cancer.
Journal: Cancer biology & medicine
Published: April 13, 2026
Tired of the same old research?
Check Latest Advances
Clinicogenomic Landscape and Function of PIK3CA, AKT1, and PTEN Mutations in Breast Cancer.
Clinicogenomic Landscape and Function of PIK3CA, AKT1, and PTEN Mutations in Breast Cancer.
Journal: JCO precision oncology
Published: April 09, 2026
View All Latest Advances
What are the latest PIK3CA-Related Overgrowth Spectrum Clinical Trials?
A Two-stage Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
A Two-stage Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Enrollment Status: Recruiting
Publish Date: April 14, 2026
Intervention Type: Drug
Study Phase: Phase 2/Phase 3

Summary: The main purpose of this study in participants with PIK3CA-mutated LyM is to assess the change in radiological response and symptom severity upon treatment with alpelisib film-coated tablets (FCT) as compared to placebo.

Match to trials
Find the right clinical trials for you in under a minute
Get started
The Phenotype and Etiology of Proteus Syndrome
The Phenotype and Etiology of Proteus Syndrome
Enrollment Status: Recruiting
Publish Date: April 14, 2026

Summary: This study will examine rare congenital disorders that involve malformations and abnormal growth. It will focus on patients with Proteus syndrome, whose physical features are characterized by overgrowth, benign tumors of fatty tissue or blood vessels, asymmetric arms or legs, and large feet with very thick soles. The study will explore the genetic and biochemical cause and course of the disease, t...

View All Clinical Trials
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved